Online inquiry

IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1999MR)

This product GTTS-WQ1999MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PVRL4 gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_030916.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 81607
UniProt ID Q96NY8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1999MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6113MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA COR-001
GTTS-WQ8981MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ15933MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ4888MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ5388MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ15554MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ12451MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ2627MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW